יתרות המזומנים של החברה: abcellera.com (ABCL)

The financial stability of AbCellera Biologics (ABCL) is constrained by the volatility of licensing revenues and the success of its partners. The cash balance history on GURU.Markets illustrates current liquidity, where the 0.79 metric reflects capital dynamics. AI algorithms and microfluidics create a technological moat that protects the business. Growth prospects are driven by the implementation of research software and long-term royalties from pharmaceutical behemoths.
פילוחי מדדים פיננסיים ומדדי שוק עבור abcellera.com (ABCL)

The AbCellera Biologics (ABCL) business model is based on milestone payments for antibody development, rendering the company independent of macroeconomic cycles. By analyzing changes in cash and cash equivalents, an investor tracks the actual balance of liquid assets and the burn rate, which allows for an assessment of the organization's financial stability and its ability to sustain research until new royalties are received from pharmaceutical partners.